Synthetic method of orbifloxacin

Through the side connection, amination, cyclization, hydrolysis and pipette shrinkage reaction of pentafluorobenzoyl chloride, the efficient synthesis of obifoxacin is achieved, solving the problems of cumbersome steps and low yield in the prior art, and reducing the cost and Waste production is suitable for industrial production.

CN118955470APending Publication Date: 2024-11-15ZHEJIANG GUOBANG PHARMA +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411015039.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing synthesis paths of obifoxacin are cumbersome, with low yields, are not suitable for industrial production, and have high cost of use.

Method used

Pentafluorobenzoyl chloride is used as raw material, and the whole process reaction without intermediate transfer is achieved through five-step reactions, such as side connection, amination, cyclization, hydrolysis, and pipetting, simplifying the synthesis steps, reducing solvent use, and adjusting pH and temperature. , and gradually synthesize obifloxacin.

Benefits of technology

It significantly improves the yield of obifoxacin, reduces waste production, reduces production costs, is suitable for industrial production, and achieves ideal results in product purity and yield.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a synthetic method of orbifloxacin, and belongs to the technical field of quinolone compounds. The preparation method comprises the following steps: by taking pentafluorobenzoyl chloride as a raw material, adding an acid-binding agent and N, N-dimethylamino ethyl acrylate, carrying out side grafting reaction at 30-40 DEG C, carrying out amination reaction on a side grafting product and cyclopropylamine at 30-40 DEG C, dissolving the obtained amide by adding a solvent, firstly adding potassium carbonate, carrying out cyclization reaction at 60-80 DEG C, then adding water, carrying out hydrolysis reaction at 40-50 DEG C, finally adding 2, 6-dimethyl piperazine, and carrying out reaction at 30-40 DEG C to obtain the 2, 6-dimethyl piperazine derivative. And after the piperazine condensation reaction is carried out at 30-60 DEG C, regulating the pH value to 1-3, and cooling to 15-30 DEG C to separate out the orbifloxacin. The method provided by the invention realizes a whole-process reaction without intermediate transfer interruption, and has the advantages of simple synthesis steps, mild reaction, less solvent use and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to a method for synthesizing orbifloxacin, and belongs to the technical field of quinolone compounds. Background Art

[0002] Orbifloxacin is a synthetic fluoroquinolone broad-spectrum antibiotic that has been approved for use in dogs. There are few synthetic routes reported in China, and currently there are two synthetic routes: The first method uses pentafluorobenzoyl chloride as the starting material, and synthesizes the third-generation animal-specific fluoroquinolone drug orbifloxacin by addition of monoethyl malonate potassium salt, condensation of triethyl orthoformate, substitution with cyclopropylamine, and then cyclization, hydrolysis and substitution of piperazine (Miyamoto, Teruyuki; Matsumoto, Jun-ichi; Chiba, Katsumi; Egawa, Hiroshi; Shibamori, Koh-ichiro; et al. Journal of Medicinal Chemistry, 1990, vol. 33, #6 p. 1645-1656; Study on the antibacterial test of veterinary quinolone drug orbifloxacin, Chen Cheng et al., "Shanghai Animal Husbandry and Veterinary Communication", 2013, No. 4, pp. 13-15). This route has cumbersome steps and low yield, and is not suitable for industrial production.

[0003] .

[0004] The second method, CN104817533A, uses sparfloxacin as a raw material, performs a diazotization reaction under the action of hydrochloric acid and sodium nitrite to obtain a diazonium salt solution; tetrafluoroboric acid is added dropwise to the diazonium salt solution, and a fluorination reaction is performed at -10°C. After the reaction is completed, the reaction solution is filtered, the filter cake is washed with ether and then dried, and the dried product is heated until no gas is generated (preferably directly heated and decomposed in an electric furnace until no gas is generated) to obtain a crude orbifloxacin product, and the crude orbifloxacin product is purified to obtain an orbifloxacin product. This route directly uses sparfloxacin as a starting material, which is costly and has a very low yield. Summary of the invention

[0005] In view of this, the present application provides a method for synthesizing orbifloxacin, which uses pentafluorobenzoyl chloride as a raw material to achieve a full-process reaction without intermediate transfer interruption, simple synthesis steps, and less solvent usage.

[0006] Specifically, the present application is implemented through the following scheme: A method for synthesizing orbifloxacin comprises the following steps: using pentafluorobenzoyl chloride as a raw material, adding an acid-binding agent and N,N-dimethylaminoethyl acrylate, carrying out a side reaction at 30-40°C, carrying out an amination reaction between the side reaction product and cyclopropylamine at 30-40°C, dissolving the obtained amine compound with a solvent, firstly adding potassium carbonate, carrying out a cyclization reaction at 60-80°C, then adding water, carrying out a hydrolysis reaction at 40-50°C, finally adding 2,6-dimethylpiperazine, carrying out a piperazine shrinkage reaction at 30-60°C, adjusting the pH to 1-3, and cooling to 15-30°C to precipitate orbifloxacin.

[0007] The above process reaction is expressed as follows: .

[0008] Further, as a preference: The acid binding agent is tri-n-propylamine, and the molar ratio of tri-n-propylamine to pentafluorobenzoyl chloride is 1.8-2.2:1.

[0009] The added molar ratio of the N,N-dimethylaminoethyl acrylate to pentafluorobenzoyl chloride is 1.2-1.5:1.

[0010] The added molar ratio of the cyclopropylamine to pentafluorobenzoyl chloride is 1.0-1.5:1 (ie 1.0-1.5 eq).

[0011] Acetic acid is added in the amination reaction to form a salt with dimethylamine generated in the reaction, promote the reaction, and inhibit the generation of dimethylamine-substituted impurities. The molar ratio of acetic acid to pentafluorobenzoyl chloride is 2.0-3.0:1 (i.e., 2.0-3.0 eq).

[0012] The solvent is any one of ethylene glycol dimethyl ether, ethylene glycol monomethyl ether, propylene glycol methyl ether, diethylene glycol diethyl ether and diethylene glycol monomethyl ether.

[0013] The molar ratio of potassium carbonate to amide is 1.5-2.5:1.

[0014] The added molar ratio of the 2,6-dimethylpiperazine to the amide is 0.9-2:1.

[0015] The piperazine reduction reaction product is added with water and a 30 wt % hydrochloric acid aqueous solution is added dropwise to adjust the pH, and the product is filtered by suction. The filter cake is washed with water to obtain a crude orbifloxacin product. The crude orbifloxacin product is dissolved with a sodium hydroxide aqueous solution and filtered by suction. The filtrate is adjusted to neutrality by adding glacial acetic acid, the precipitated solid is dissolved with glacial acetic acid, the filtrate is filtered by suction and the pH is adjusted to 8.0-8.5 with ammonia water, potassium hydroxide or a 10% sodium hydroxide aqueous solution, and the finished orbifloxacin is obtained by suction filtration.

[0016] The present invention significantly improves product yield, reduces three wastes, reduces costs, and is suitable for industrial production. Its beneficial effects are summarized as follows: (1) Pentafluorobenzoyl chloride is used as a raw material, and orbifloxacin is obtained through a five-step reaction of ligation, amination, cyclization, hydrolysis, and piperylation. During the reaction, the reaction is transferred in the form of a fluid. Through two cascade reactions of ligation-amination, cyclization-hydrolysis-piperidinization, no solid intermediates are produced, which is suitable for industrial production.

[0017] (2) The synthesis steps are few, the reaction conditions are mild, less solvent is used, and the wastewater generation is reduced. DETAILED DESCRIPTION

[0018] In order to make the technical problems, technical solutions and beneficial effects to be solved by this application clearer, the technical solutions of this application will be further described in detail below in combination with the specific cases in the embodiments of this application. It should be understood that the specific embodiments described herein are only used to explain this application and are not used to limit the technical solutions of this application. Based on the embodiments in this application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.

[0019] Example 1

[0020] The synthesis process of orbifloxacin in this embodiment is roughly divided into three stages: (1) Preparation of amides: Add 30.00 g (0.130 mol) of pentafluorobenzoyl chloride and 37.25 g (0.260 mol) of tri-n-propylamine to a 500 ml four-necked bottle, and add 22.34 g (0.156 mol) of N, N-dimethylamino ethyl acrylate dropwise while controlling the temperature of the feed liquid to be around 25°C. After the addition is complete, control the reaction temperature to be around 35°C and keep warm for 4 hours. After the reaction is complete, add 150 g of toluene and stir evenly, control the temperature of the feed liquid to be around 35°C and add 15.60 g (0.260 mol) of glacial acetic acid, stir for 10 minutes, and then control the temperature of the feed liquid to be around 25°C and add 8.91 g (0.156 mol) of cyclopropylamine dropwise, and keep warm for 1 hour at around 35°C. After the insulation is complete, add 120 g of water, add hydrochloric acid dropwise to adjust the pH to around 2, stir for 15 minutes, separate the liquids, retain the organic layer, wash the organic layer twice with 40 g of water, and recover the toluene under reduced pressure to dryness to obtain the aminated product.

[0021] (2) Preparation of crude orbifloxacin: In a 500ml four-necked bottle, add 30.00g (0.086mol) of amine and 150g of diethylene glycol diethyl ether, stir evenly, add 23.77g (0.172mol) of potassium carbonate, heat to 75℃ and react for 4h, and the reaction is complete. Cool to 50℃, add 1g of water, and keep warm at 45℃ for 2h. After the insulation is completed, add 14.73g (0.129mol) of 2,6-dimethylpiperazine, and react at 45℃ for 4h. After the reaction is completed, add 200g of water, add hydrochloric acid dropwise to adjust the pH to 2, cool to 25℃ and place for 1h, filter, and wash the filter cake with 50g of water to obtain crude orbifloxacin.

[0022] (3) Refining of Orbifloxacin: Put the crude orbifloxacin in a 1000ml four-necked flask, add 600.00g of water, add 10% sodium hydroxide aqueous solution to adjust to complete dissolution, add 1.00g of activated carbon, stir for 1 hour, and filter with suction. The filtrate is adjusted to pH 7.0 with reagent hydrochloric acid, stirred for 1 hour after adjustment, and filtered with suction. Add 600g of water to the filter cake, add glacial acetic acid dropwise until dissolved, add 1.00g of activated carbon and stir for 1 hour, filter with suction, adjust the pH of the filtrate to pH 8.0 with 10% sodium hydroxide aqueous solution, filter with suction, and dry the filter cake under vacuum decompression to obtain 29.26g of orbifloxacin, with a molar yield of 86.05% and a liquid content of 99.99%.

[0023] The above-mentioned synthesis process uses two series reactions of directly synthesizing an amine through a tandem reaction of side-joining-amination and directly synthesizing a crude product through a tandem reaction of cyclization-hydrolysis-piperidinization. No solid intermediates are taken out, and when the preparation processes of the amine, the crude product and the fine product are handed over, the materials are transferred in the form of fluid, which lays the reaction foundation for the full-process synthesis of orbifloxacin.

[0024] Example 2

[0025] The configuration of this embodiment is the same as that of embodiment 1, except that in step (2), 200 g of ethylene glycol dimethyl ether is used as the solvent, and 28.26 g of orbifloxacin is obtained, with a molar yield of 83.11% and a liquid content of 99.99%.

[0026] Compared with Example 1, in this embodiment, the solvent is replaced by ethylene glycol dimethyl ether by diethylene glycol diethyl ether, and other conditions are roughly the same. A high purity can still be maintained, but the yield is reduced, indicating that when diethylene glycol diethyl ether is used as a solvent, it can have a more significant positive effect on the improvement of the reaction yield.

[0027] Example 3

[0028] The configuration of this embodiment is the same as that of embodiment 1, except that in step (2), after adding 2,6-dimethylpiperazine, the reaction temperature is 70° C., and 18.29 g of orbifloxacin is obtained, with a molar yield of 53.79% and a liquid content of 99.98%.

[0029] Compared with Example 1, the piperazine reduction reaction temperature in this embodiment is increased from 45°C to 70°C, and the yield is significantly reduced. After other experiments, it is concluded that the yield of the piperazine reduction reaction at 30-60°C (such as 45°C in Example 1) is ideal.

[0030] Example 4

[0031] The configuration of this embodiment is the same as that of embodiment 1, except that in step (2), the mass of 2,6-dimethylpiperazine input is 16.76 g (0.147 mol), and 26.38 g of orbifloxacin is obtained, with a molar yield of 77.58% and a liquid content of 99.97%.

[0032] Example 5

[0033] The configuration of this embodiment is the same as that of embodiment 1, except that in step (1), the amount of the amide added is 7.80 g (0.137 mol), and 25.36 g of orbifloxacin is obtained, with a molar yield of 74.58% and a liquid content of 99.98%.

[0034] Compared with Example 1, Example 4 increases the amount of 2,6-dimethylpiperazine added, and the molar ratio of amide to 2,6-dimethylpiperazine is increased from 1:1.5 in Example 1 to 1:1.7 in Example 4; while Example 5 increases the amount of amide added, and the molar ratio of amide to 2,6-dimethylpiperazine is reduced from 1:1.5 in Example 1 to 1:0.9 in Example 4.

[0035] The purity of the products was maintained above 99.9%, but the yield of the final product in Example 1 was 86.05%, in Example 4 it was 77.58%, and in Example 5 it was 74.58%, indicating that in the piperazine-condensation reaction, the amount of organic reagents such as 2,6-dimethylpiperazine does not need to be increased blindly to achieve the synthesis needs. In the present application, the ratio of amide to 2,6-dimethylpiperazine can be controlled at a relatively low level of 1:1.5, and both the yield and purity can achieve relatively ideal results.

[0036] Example 6

[0037] The configuration of this embodiment is the same as that of embodiment 1, except that in step (1), the reaction condition after adding ethyl N,N-dimethylaminoacrylate is to keep the temperature at 60°C for 2h, and 20.57g of orbifloxacin is obtained, with a molar yield of 68.49% and a liquid content of 99.98%.

[0038] In the scheme provided in the present application, the side reaction temperature is appropriately controlled at 30-40°C; when the side reaction temperature is increased from 35°C in Example 1 to 60°C in Example 6, the temperature increase does not increase the reaction activity as expected. Although the purity is still maintained at more than 99.9%, the molar yield decreases significantly, indicating that the reaction system of the present application can be realized at relatively mild room temperature or slightly above room temperature, and the reaction conditions are mild.

[0039] Example 7

[0040] The configuration of this embodiment is the same as that of embodiment 1, except that in step (2), the amount of potassium carbonate added is 17.83 g (0.129 mol), and 24.65 g of orbifloxacin is obtained, with a molar yield of 72.49% and a liquid content of 99.99%.

[0041] In Example 7, when the molar ratio of potassium carbonate to amide is 1.5:1, the yield is lower than the yield of potassium carbonate to amide in Example 1 when the molar ratio is 2:1. The optimal molar addition ratio of potassium carbonate to amide is preferably controlled at 2:1.

[0042] Example 8

[0043] The configuration of this embodiment is the same as that of embodiment 1, except that in step (3), ammonia water is used to adjust the pH to about 8.0, and 27.84 g of orbifloxacin is obtained, with a molar yield of 81.87% and a liquid content of 99.99%.

[0044] During the refining process, ammonia water, sodium hydroxide, potassium hydroxide and other solutions can be used. Compared with Example 1, under the same conditions, after the ammonia water is used to adjust the neutrality in this embodiment, the yield is relatively weaker than the sodium hydroxide aqueous solution in Example 1.

[0045] The above-mentioned embodiments only express several feasible implementation methods of the present invention, and the description is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention, and the embodiments are not used to limit the scope of protection in the claims of the present invention. For ordinary technicians in this field, several modifications and improvements can be made without departing from the concept of the present invention, and all equivalent implementations or changes that do not depart from the present invention should be included in the technology of the present invention.

Claims

1. A method for synthesizing orbifloxacin, characterized in that: Pentafluorobenzoyl chloride is used as a raw material, an acid binding agent and N,N-dimethylamino ethyl acrylate are added, a side reaction is carried out at 30-40°C, the side reaction product is reacted with cyclopropylamine at 30-40°C for amination, the obtained amide is dissolved in a solvent, potassium carbonate is first added, a cyclization reaction is carried out at 60-80°C, water is then added, a hydrolysis reaction is carried out at 40-50°C, and finally 2,6-dimethylpiperazine is added, a piperazine shrinkage reaction is carried out at 30-60°C, the pH is adjusted to 1-3, and the temperature is lowered to 15-30°C to precipitate orbifloxacin.

2. A method for synthesizing orbifloxacin according to claim 1, characterized in that: The acid binding agent is tri-n-propylamine, and the molar ratio of tri-n-propylamine to pentafluorobenzoyl chloride is 1.8-2.2:

1.

3. A method for synthesizing orbifloxacin according to claim 1, characterized in that: The added molar ratio of the N,N-dimethylaminoethyl acrylate to pentafluorobenzoyl chloride is 1.2-1.5:

1.

4. The method for synthesizing orbifloxacin according to claim 1, characterized in that: The added molar ratio of the cyclopropylamine to pentafluorobenzoyl chloride is 1.0-1.5:

1.

5. The method for synthesizing orbifloxacin according to claim 1, characterized in that: Acetic acid is added in the amination reaction, and the molar ratio of acetic acid to pentafluorobenzoyl chloride is 2.0-3.0:

1.

6. The method for synthesizing orbifloxacin according to claim 1, characterized in that: The solvent is any one of ethylene glycol dimethyl ether, ethylene glycol monomethyl ether, propylene glycol methyl ether, diethylene glycol diethyl ether and diethylene glycol monomethyl ether.

7. The method for synthesizing orbifloxacin according to claim 1, characterized in that: The molar ratio of potassium carbonate to amide is 1.5-2.5:

1.

8. The method for synthesizing orbifloxacin according to claim 1, characterized in that: The added molar ratio of the 2,6-dimethylpiperazine to the amide is 0.9-2:

1.

9. A method for synthesizing orbifloxacin according to any one of claims 1 to 8, characterized in that: Here are the steps: Step 1, preparation of amide: Tri-n-propylamine is added to pentafluorobenzoyl chloride, and N,N-dimethylaminoethyl acrylate is added dropwise at a feed liquid temperature of 20-30°C. After the addition is completed, the reaction temperature is controlled at 30-40°C and the reaction is kept warm. After toluene is added and stirred evenly, glacial acetic acid is added to the feed liquid temperature of 30-40°C, and the reaction is completed by stirring. Cyclopropylamine is added dropwise at a feed liquid temperature of 20-30°C, and the reaction is completed by keeping warm at 30-40°C. Water is added, and hydrochloric acid is added dropwise to adjust the pH to 1-3. The mixture is stirred, separated, and the organic layer is retained. After the organic layer is washed with water twice, toluene is recovered under reduced pressure until dry to obtain an aminated product. Step 2, preparation of crude orbifloxacin: Add a solvent to the amine of step 1, stir evenly, then add potassium carbonate, heat to 70-75°C to complete the reaction, cool to 50°C, add water, keep warm at 40-50°C to complete the hydrolysis, then add 2,6-dimethylpiperazine, react at 40-50°C, add water, add hydrochloric acid dropwise to adjust the pH to 1-3, cool to 20-25°C, place, filter, wash the filter cake with water to obtain a crude orbifloxacin, and purify the crude product to obtain a finished orbifloxacin.

10. The method for synthesizing orbifloxacin according to claim 9, characterized in that: The refining comprises: adding water and 10% sodium hydroxide aqueous solution to the crude orbifloxacin to adjust the pH to be completely dissolved, adding activated carbon, stirring, and filtering, adjusting the pH of the filtrate to 7.0-7.5, stirring, and filtering after adjustment; adding water and glacial acetic acid to the filter cake until it is dissolved, adding activated carbon, stirring, and filtering, adjusting the pH of the filtrate to 8.0-8.5, filtering, and drying the filter cake under vacuum to obtain orbifloxacin.